A Cancer Drug Shows Promise, at a Price That Many Can't Pay - New York Times

Read the entire article to see how Genentech is completely pushing the envelope in pricing of avastin...and get mad because you and I as taxpayers will be paying much of the cost. Get mad because patients with high co-payments may not be able to afford it. Get mad because the current medicare drug benefit reform does not address price controls for drug manufacturers. Get mad because Genentech is using every possible means to prevent retina specialists from using avastin for macular degeneration (at a cost of ~30$/injection) so that it can force ophthalmologists to use Lucentis when it comes to market (which has in all likelihood the same efficacy and safety as avastin) at a price of probably over 2000$/injection every four weeks.
A culture of greed, indeed...

A Cancer Drug Shows Promise, at a Price That Many Can't Pay - New York Times: "Doctors are excited about the prospect of Avastin, a drug already widely used for colon cancer, as a crucial new treatment for breast and lung cancer, too. But doctors are cringing at the price the maker, Genentech, plans to charge for it: about $100,000 a year."